These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 21195172)

  • 21. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
    Kavlock R; Dix D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary on ''Toxicity testing in the 21st century: a vision and a strategy'': stem cells and cell-cell communication as fundamental targets in assessing the potential toxicity of chemicals.
    Trosko JE
    Hum Exp Toxicol; 2010 Jan; 29(1):21-9. PubMed ID: 20061464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory toxicology in the twenty-first century: challenges, perspectives and possible solutions.
    Tralau T; Oelgeschläger M; Gürtler R; Heinemeyer G; Herzler M; Höfer T; Itter H; Kuhl T; Lange N; Lorenz N; Müller-Graf C; Pabel U; Pirow R; Ritz V; Schafft H; Schneider H; Schulz T; Schumacher D; Zellmer S; Fleur-Böl G; Greiner M; Lahrssen-Wiederholt M; Lampen A; Luch A; Schönfelder G; Solecki R; Wittkowski R; Hensel A
    Arch Toxicol; 2015 Jun; 89(6):823-50. PubMed ID: 25820917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and future needs for developmental toxicity testing.
    Makris SL; Kim JH; Ellis A; Faber W; Harrouk W; Lewis JM; Paule MG; Seed J; Tassinari M; Tyl R
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):384-94. PubMed ID: 21922641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives.
    Blaauboer BJ
    Toxicol Lett; 2008 Aug; 180(2):81-4. PubMed ID: 18586419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the proposed EU regulation concerning biocide products and its opportunities for alternative approaches and a toxicology for the 21st century.
    Ferrario D; Rabbit RR
    ALTEX; 2012; 29(2):157-72. PubMed ID: 22562488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety evaluation of cosmetics in the EU. Reality and challenges for the toxicologist.
    Pauwels M; Rogiers V
    Toxicol Lett; 2004 Jun; 151(1):7-17. PubMed ID: 15177635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges of using pluripotent stem cells for safety assessments of substances.
    Vojnits K; Bremer S
    Toxicology; 2010 Mar; 270(1):10-7. PubMed ID: 20004228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
    Leighton JK
    Int J Toxicol; 2005; 24(3):153-5. PubMed ID: 16040567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Commentary on ''Toxicity testing in the 21st century: a vision and a strategy''.
    Phalen RF
    Hum Exp Toxicol; 2010 Jan; 29(1):11-4. PubMed ID: 20061462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity testing in the 21st century: implications for human health risk assessment.
    Krewski D; Andersen ME; Mantus E; Zeise L
    Risk Anal; 2009 Apr; 29(4):474-9. PubMed ID: 19144067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein biomarkers for in vitro testing of toxicology.
    Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K
    Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: genotoxicity. A COLIPA analysis.
    Pfuhler S; Kirst A; Aardema M; Banduhn N; Goebel C; Araki D; Costabel-Farkas M; Dufour E; Fautz R; Harvey J; Hewitt NJ; Hibatallah J; Carmichael P; Macfarlane M; Reisinger K; Rowland J; Schellauf F; Schepky A; Scheel J
    Regul Toxicol Pharmacol; 2010; 57(2-3):315-24. PubMed ID: 20382194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bringing toxicology into the 21st century: a global call to action.
    Seidle T; Stephens ML
    Toxicol In Vitro; 2009 Dec; 23(8):1576-9. PubMed ID: 19540332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health.
    Harvey PW; Everett DJ
    Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):145-65. PubMed ID: 16522525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications of emerging technologies in toxicology and safety assessment.
    Reynolds VL
    Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity testing in the 21st century: how will it affect risk assessment?
    Rhomberg LR
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):361-75. PubMed ID: 20574908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A discussion of the impact of US chemical regulation legislation on the field of toxicity testing.
    Sullivan K; Beck N; Sandusky C; Willett C
    Toxicol In Vitro; 2011 Sep; 25(6):1231-6. PubMed ID: 21624455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview: developmental toxicology: new directions.
    Shuey D; Kim JH
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):381-3. PubMed ID: 21770024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.